Related Experiment Video

Updated: Jun 17, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.6K

AP-2α gene deregulation is associated with renal cell carcinoma patient survival

Po-Hung Lin1,2,3, Chin-Hsuan Hsieh1, Kai-Jie Yu1,2,4

  • 1Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, LinKou Branch. No. 5, Fushing St, Taoyuan, 333, Taiwan.

BMC Cancer
|August 7, 2024
PubMed
Abstract

Insights

Activator protein (AP)-2α expression is deregulated in renal cell carcinoma (RCC) and linked to patient survival. Lower AP-2α mRNA levels correlate with poorer outcomes, suggesting its role in RCC development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Renal cell carcinoma (RCC) is a deadly urologic tumor with high metastatic potential and relapse rates.
  • While surgery and targeted therapies improve survival, the molecular drivers of RCC remain unclear.
  • Understanding RCC pathogenesis is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the clinical significance of the transcription factor activator protein (AP)-2α in renal cell carcinoma (RCC).
  • To determine the relationship between AP-2α expression, methylation, and patient survival outcomes in RCC.
  • To explore the potential role of AP-2α in the pathogenesis of RCC.

Main Methods:

  • Utilized methylated CpG island recovery assays and microarray analysis to assess AP-2α.
  • Employed COBRA and RT-qPCR assays to quantify AP-2α mRNA expression in RCC tissues.
  • Performed multivariate analyses to evaluate AP-2α as a prognostic factor.

Main Results:

  • A negative correlation was observed between AP-2α mRNA expression levels and DNA methylation status.
  • AP-2α mRNA expression was identified as a significant risk factor for overall survival in RCC patients.
  • Reduced AP-2α mRNA levels were associated with decreased disease-free survival in both overall RCC and clear cell RCC subtypes.

Conclusions:

  • AP-2α expression is deregulated in renal cell carcinoma.
  • AP-2α expression levels are significantly associated with overall and disease-free survival in RCC patients.
  • These findings highlight AP-2α as a potential biomarker and suggest its involvement in RCC pathogenesis.
Keywords:
AP-2αOverall survivalPrognostic factorRenal cell carcinomaTFAP2A

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K
Serum and Plasma Copy Number Detection Using Real-time PCR09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.4K

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K